# Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

> **NCT04063449** · NA · UNKNOWN · sponsor: **Dong Wang** · enrollment: 170 (estimated)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** endostar/PD-1 inhibitor
- **DRUG:** endostar

## Key facts

- **NCT ID:** NCT04063449
- **Lead sponsor:** Dong Wang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-20
- **Primary completion:** 2020-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2019-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04063449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04063449, "Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04063449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*